Driven by Care,
Powered by Innovation

Mr. Ofer Gonen is the CEO of MediWound (Nasdaq: MDWD), bringing more than 20 years of executive management and corporate development experience in the biopharmaceutical industry. Prior to MediWound, Mr. Gonen was the CEO of Clal Biotechnology Industries (TASE: CBI) and a managing partner at the Anatomy Medical Technology Fund. He is also the co-founder of Cactus Acquisition Corp. 1 (Nasdaq: CCTS) and ARTE Venture Group.

Mr. Gonen has held board positions at leading life sciences companies, including Gamida Cell (Nasdaq: GMDA), Anchiano Therapeutics (Nasdaq: ANCN), Elicio Therapeutics (Nasdaq: ELTX), and MediWound. He also served on the boards of Colbar and Cadent, both of which were successfully acquired by Johnson & Johnson and Novartis, respectively.

Mr. Gonen holds a B.Sc. in Physics, Mathematics, and Chemistry from the Hebrew University of Jerusalem and an M.A. in Economics and Finance from Tel Aviv University. He is an alumnus of the prestigious Talpiot program of the Israeli Defense Forces.

Dr. Ety Klinger is the Chief Research and Development Officer at MediWound. Before joining MediWound, she served as Vice President of R&D at Proteologics Ltd., where she led discovery projects in collaboration with GlaxoSmithKline and Teva. She spent 17 years in leadership positions within Teva’s global innovative R&D division and represented the company on the boards of multiple biotech firms.

Dr. Klinger has led R&D projects across all stages of development and played a pivotal role in the development of Copaxone® for multiple sclerosis. As Senior Director at Teva, she was a member of the global innovative R&D management team and led the MS and Autoimmune Diseases therapeutic area.

She holds a B.Sc. in Biology from the Hebrew University of Jerusalem, an M.Sc. and Ph.D. in Biochemistry from Tel Aviv University, and an MBA from the Kellogg School of Management at Northwestern University and Tel Aviv University.

Dr. Shmulik Hess is the Chief Operating Officer & Chief Commercial Officer at MediWound. He brings over two decades of expertise in drug development and commercial operations within the healthcare sector. Before joining MediWound, he served as CEO at Tabby Therapeutics, Enlivex Therapeutics (Nasdaq: ENLV), and Valin Technologies. He also held a global operations executive role at SciGen Ltd. (acquired by VBI Vaccines).

Dr. Hess has a strong background in operational strategy, sales, and commercial leadership in the global biopharma industry. He is the inventor of multiple patents and the author of numerous peer-reviewed scientific publications.

Dr. Hess holds a Ph.D. in Pharmaceutical Science from the Hebrew University of Jerusalem and was a research fellow at the Harvard-MIT Health Sciences and Technology (HST) program.

Dr. Robert J. Snyder (DPM, MSc, MBA, CWSP, FFPM RCPS, Lorem ipsum dolor sit) serves as Chief Medical Officer at MediWound. He is Dean, Professor, Director of Clinical Research, and Fellowship Director in Wound Care and Research at Barry University School of Podiatric Medicine. Board-certified in foot and ankle surgery by the American Board of Podiatric Surgery and as a wound specialist, Dr. Snyder has held leadership roles including past-president of the Association for the Advancement of Wound Care and the American Board of Wound Management.

Dr. Snyder earned his MBA in Health Management from The George Washington University and completed the Global Clinical Scholars Research Training Program at Harvard Medical School. He has a MSc in Wound Management and Tissue Science from Cardiff University/ University of Wales College of Medicine. A recognized key opinion leader, he lectures extensively in the U.S. and internationally and has authored over 180 peer-reviewed papers and book chapters on wound care. He is the recipient of the Dr. Robert Warriner Memorial Award for excellence in wound management.

Dr. Snyder serves as Associate Editor for JAPMA and sits on the editorial advisory boards of Ostomy Wound Management and Wounds. He also periodically reviews for The Lancet and NEJM. As Principal Investigator, he has led over 65 randomized controlled trials on innovative wound healing modalities and products.

Ms. Hani Luxenburg serves as the Chief Financial Officer of MediWound, bringing over two decades of leadership experience in financial strategy, accounting, and operational management. She has a strong track record of driving business growth, optimizing financial performance, and enhancing corporate financial strategy in the technology and life sciences sectors.

Before joining MediWound, Ms. Luxenburg served as the Chief Financial Officer at BIRD Aerosystems and held senior finance roles at AstraZeneca, Alvarion Technologies Ltd., and Ernst & Young.

Ms. Luxenburg holds a Bachelor of Arts in Economics and Accounting from the University of Haifa and a Bachelor of Law from the Interdisciplinary Center (IDC). She is a Certified Public Accountant (CPA) and a member of the Israel Bar Association.

Mr. Yaron Meyer is the Executive Vice President and General Counsel at MediWound. He brings extensive legal experience in the biotechnology sector, with a strong focus on corporate law, public company operations, capital markets and corporate governance. Before joining the Company, he was Corporate Secretary at Clal Biotechnology Industries Ltd. (CBI) from 2008 to 2013, and General Counsel and Corporate Secretary at D-Pharm Ltd. from 2010 to 2013. He also served as Legal Counsel at Clal Industries Ltd. from 2008 to 2010. Earlier in his career, Mr. Meyer worked as an associate at Shibolet & Co. Advocates from 2005 to 2008.

Mr. Meyer is a member of the Israel Bar Association and holds an LL.B. from Haifa University.

Mr. Barry Wolfenson serves as Executive Vice President of Strategy & Corporate Development at MediWound. He co-founded vTail Healthcare Telecommunications, a healthcare-wide digital platform with an initial focus on the advanced wound care market. Mr. Wolfenson also served as a Strategic Advisor to Origin, Inc. on their Phase III-ready IonoJet™ technology for diabetic foot ulcers.

He currently sits on the Board of Directors at SANO Diagnostics, having previously served as its CEO. SANO Diagnostics is a point-of-care inflammation diagnostic platform focused on chronic wounds. Mr. Wolfenson spent 13 years at Derma Sciences in roles of increasing responsibility, playing a key role in building the company’s advanced wound care business prior to its acquisition by Integra Life Sciences.

Mr. Wolfenson began his career as an analyst at Accenture and later held positions at Bristol Myers Squibb. He holds an MBA from the Stephen M. Ross School of Business at the University of Michigan and a B.A. in Economics and Pre-Med from Franklin & Marshall College.

Andrey Kon serves as Vice President Plant Manager at MediWound. He has led the company’s production operations since its inception in 2001, bringing over 20 years of experience in the biotech industry with a focus on manufacturing and operational management.

Before joining MediWound, Mr. Kon served as Head of Production at Omrix Pharmaceuticals Inc., where he managed key manufacturing processes.

Mr. Kon holds an M.Sc. in Biotechnology from the St. Petersburg Pharmaceutical Institute.

Keren David-Zarbiv is the Vice President of Clinical Affairs at MediWound. She has over 20 years of experience in clinical operations, regulatory compliance, and strategic management. As the Vice President of Clinical Affairs at MediWound she is responsible for overseeing the development and implementation of clinical strategies that ensure high-quality patient care and align with the organization’s mission and goals. She brings a strong background in clinical research and development within the biotechnology sector. In her role, Keren has played a pivotal part in leading successful BLA submissions and securing regulatory approvals, demonstrating a profound understanding of the complexities involved in bringing innovative therapies to market.

Ms. David-Zarbiv holds a B.Sc. and M.Sc. with distinction from the Faculty of Biotechnology and Food Engineering at the Technion – Israel Institute of Technology.

Alicia Torrenova serves as Vice President of European Operations at MediWound. Prior to this role, she successfully managed operations in Spain, Portugal, and LATAM countries as Business Unit Manager. Before joining MediWound, Ms. Torrenova was Country Manager for LifeCell in Spain and Portugal, where she introduced biological matrices for soft tissue repair.

Ms. Torrenova began her career at Coloplast, where she served as Marketing and Sales Manager, working closely with surgeons, national patient collectives, and marketing authorities to launch and develop the market for breast cancer products.

She holds a Bachelor’s degree in Business Administration and Management from the Sorbonne University in Paris and a Master’s degree in Business Management and Sales from the CEF School of Business in Madrid.

Aya Ben Yaakov serves as Vice President of Regulatory Affairs at MediWound. Before taking on her current role, Aya led clinical trials for both the NexoBrid and EscharEx programs in the Clinical Department.

Her notable achievements include leading the Phase 3 NexoBrid pediatric study and the submissions to regulatory authorities such as the EMA and FDA to secure approval for NexoBrid’s use in pediatric patients.

Aya holds a B.Sc. in Nutritional Sciences with honors from the Hebrew University of Jerusalem. She also earned an M.Sc. in Medical Sciences and a Ph.D. in Pathology from Tel Aviv University, where her doctoral research focused on impaired wound healing in diabetic patients.

Alexandra (Sandra) Teplitsky is the Vice President of Quality Assurance at MediWound.. With over a decade of experience in the biotechnology and pharmaceutical industries, Sandra brings extensive expertise in regulatory compliance, quality assurance, process enhancement, and risk-centered methodologies.

She has been instrumental in guiding rigorous on-site inspections conducted by regulatory bodies such as the FDA, EMA, and PMDA, successfully steering them toward approval. Sandra’s track record highlights her pivotal role in elevating the company’s quality standards while her strategic vision propels MediWound toward its future objectives.

Sandra holds a Master of Science in Chemical Engineering from Ben-Gurion University.

Hagit Mashiach has served in senior human resources leadership roles across the high-tech, fintech, and life sciences sectors for over two decades. Most recently, she was Vice President of Human Resources at Verifone, where she led strategic HR initiatives across the Israeli site in alignment with global operations. Prior to Verifone, from 2014 to 2023, Ms. Mashiach served as Director of Human Resources EMEA at Amobee, a global digital marketing technology company. In this role, she managed HR teams in Israel and the UK and partnered closely with global leadership in the U.S. and Singapore. She was responsible for post-acquisition merger, developing and implementing HR strategies across several sites. From 2009 to 2014, Ms. Mashiach was Head of HR at Syngenta, a multinational company in the crop protection and seeds sector, where she led the HR integration following a major acquisition. She managed international HR across multiple regions including Turkey, Spain, U.S, Mexico, and played a key role in leading cultural and organizational transformation. Ms. Mashiach holds a B.A. in Behavioral Sciences from Ben-Gurion University, an M.B.A. with a specialization in Human Resources, and an M.A. in Organizational Development and Consultancy, both from the College of Management Academic Studies.